Lucid Diagnostics (LUCD) Income from Continuing Operations (2020 - 2026)
Lucid Diagnostics (LUCD) posted Income from Continuing Operations of 13909000.0 for Q1 2026, up 14.49% on a QoQ basis from 16266000.0 in Q4 2025, and up 48.31% year-over-year from 9378389.05 in Q1 2025.
Lucid Diagnostics (LUCD) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Lucid Diagnostics' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 13909000.0 for Q1 2026.
- Quarterly Income from Continuing Operations rose 48.31% year-over-year to 13909000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 45011000.0 (up 27.2% YoY) and the FY2025 annual result came in at 58010000.0, down 27.41% from the prior year.
- Income from Continuing Operations was 13909000.0 for Q1 2026 at Lucid Diagnostics, up from 16266000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 4439000.0 in Q2 2025 and bottomed at 26908000.0 in Q1 2025.
- A 5-year average of 13310882.35 and a median of 12371000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations sank 235.89% — and 2025, when it jumped 59.66%.
- Lucid Diagnostics' Income from Continuing Operations stood at 14928000.0 in 2022, then advanced by 27.45% to 10830000.0 in 2023, then dropped by 6.57% to 11541000.0 in 2024, then slumped by 40.94% to 16266000.0 in 2025, then advanced by 14.49% to 13909000.0 in 2026.
- Business Quant data shows LUCD's Income from Continuing Operations at 13909000.0 in Q1 2026, 16266000.0 in Q4 2025, and 10397000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 380.70 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 199.50 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 273.95 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 411.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Lucid Diagnostics | 133.09 Mn | 105.22 Mn | -325,000.00 | -13.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.91 Mn |
| Dec 31, 2025 | -16.27 Mn |
| Sep 30, 2025 | -10.40 Mn |
| Jun 30, 2025 | -4.44 Mn |
| Mar 31, 2025 | -26.91 Mn |
| Dec 31, 2024 | -11.54 Mn |
| Sep 30, 2024 | -12.37 Mn |
| Jun 30, 2024 | -11.01 Mn |
| Mar 31, 2024 | -10.61 Mn |
| Dec 31, 2023 | -10.83 Mn |
| Sep 30, 2023 | -14.21 Mn |
| Jun 30, 2023 | -11.38 Mn |
| Mar 31, 2023 | -16.25 Mn |
| Dec 31, 2022 | -14.93 Mn |
| Sep 30, 2022 | -14.35 Mn |
| Jun 30, 2022 | -14.62 Mn |
| Mar 31, 2022 | -12.27 Mn |
| Dec 31, 2021 | -11.31 Mn |
| Sep 30, 2021 | -6.96 Mn |
| Jun 30, 2021 | -6.16 Mn |